[Mechanisms and prevention strategies of relapse and resistance after BCMA-CAR-T cell in multiple myeloma] [0.03%]
BCMA-CAR-T细胞治疗后多发性骨髓瘤复发和耐药的机制及预防策略
L Zhang,Y Wang,K L Xu
L Zhang
B J Ding,L Liu,M J Li et al.
B J Ding et al.
[SET-NUP214-positive pediatric acute myeloid leukemia: a report of two cases] [0.03%]
SET-NUP214阳性儿童急性髓系白血病两例报告
Y Z Zheng,J J Wen,L Y Wang et al.
Y Z Zheng et al.
[Systemic light chain amyloidosis with amyloid myopathy as the main manifestation: a case report] [0.03%]
以肌病表现为主要表现的系统性轻链型淀粉样变1例
W Zhang,L J Jiang,Y P Ma et al.
W Zhang et al.
[Clinical outcomes of 31 patients with acute leukemia receiveing modified conditioning regimen incorporating cladribine for autologous hematopoietic stem cell transplantation] [0.03%]
接受含克拉屈滨预处理方案的自体造血干细胞移植治疗急性白血病的临床结果分析(31例)
Y Y Shi,G X Zhang,Y He et al.
Y Y Shi et al.
[The correlation between post-allo-HSCT CMV infection and the difference affinity of donor HLA-type recognition of CMV antigen peptide in children] [0.03%]
移植物抗宿主病CMV感染与儿童供者HLA类型对CMV抗原肽不同亲和力的相关性研究
L Yang,Z Wang,S Wu et al.
L Yang et al.
Objective: To explore the correlation between the affinity while donor's HLA type recognizing different cytomegalovirus (CMV) antigen peptide and the occurrence of CMV infection after allogeneic hematopoietic stem cell transplantation (allo...
[Efficacy and safety of vemurafenib in the treatment of BRAF(V600E)-mutated Erdheim-Chester disease] [0.03%]
Vemurafenib治疗BRAF(V600E)突变型Erdheim-Chester病的有效性和安全性
T Liu,T H He,N Niu et al.
T Liu et al.
Objective: To evaluate the safety and efficacy of vemurafenib in the treatment of BRAF(V600E)-mutated Erdheim-Chester disease (ECD) . Methods: We retrospectively analyzed the clinical data, response rate, adverse events and survival of 12 p...
[Effects of glucocorticoids on the proliferation of CD19 CAR-T cells targeting B-cell tumor cell lines] [0.03%]
糖皮质激素对靶向B细胞肿瘤细胞系的CD19 CAR-T细胞增殖的影响
H B Deng,M J Liu,Y Y Jiang et al.
H B Deng et al.
Objective: To evaluate the effects of glucocorticoids (dexamethasone and methylprednisolone) on the proliferation of CD19 Chimeric antigen receptor (CAR) modified T cells in vitro. Methods: Peripheral blood mononuclear cells from healthy vo...
[Infectious complications following chimeric antigen receptor T-cell therapy for a hematologic malignancy within 28 days] [0.03%]
CAR-T细胞治疗血液肿瘤后28天内的感染并发症
Y N Li,M Y Du,C G Li et al.
Y N Li et al.
Objective: To explore the incidence, clinical and microbiological characteristics and risk factors of infection in patients with acute lymphoblastic (ALL) , non-Hodgkin lymphoma (NHL) , and multiple myeloma (MM) within 28 days after CAR-T c...